-
-
-
-
-
-
-
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
-
-
-
-
-
-
-
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
-
-
-
-
-
-
-
Veru to Present at the 2024 Cantor Global Healthcare Conference
-
-
-
-
-
-
-
Form S-3/A VERU INC.
-
-
-
-
-
-
-
Form S-3 VERU INC.
-
-
-
-
-
70,527 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

